Navigation Links
Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
Date:5/19/2009

Updated Safety data presented at BIO International Convention in Atlanta

ATLANTA, May 19 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) released updated safety data today from its pixantrone phase III 301 EXTEND trial demonstrating the effectiveness of pixantrone in patients with relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) for whom anthracycline-related drugs are typically not to be used due to the increased risk of cardiac failure.

As noted during the presentation of Craig Philips, President of CTI, "The standard chemotherapy regimen (CHOP) for this disease exposes patients to less than or equal to 300mg/m2 of doxorubicin, a dose at which 5.6% of patients are expected to develop congestive heart failure (CHF). At cumulative doses of doxorubicin in excess of 600mg/m2, 48% of patients develop CHF."

"With these background statistics, we examined the occurrence of CHF from any cause among PIX 301 recipients who received prior treatment at standard doxorubicin doses (<=300mg/m2) along with those pixantrone recipients who had received extensive prior doxorubicin treatment compared to historically reported rates when treated with standard doxorubicin," stated Mr. Philips. "Despite patients receiving a median total cumulative doxorubicin equivalent dose of 535mg/m2, the frequency of CHF among PIX 301 recipients was non-dose dependant and was markedly lower than that reported for doxorubicin at similar levels of treatment."

At a cumulative total doxorubicin equivalent exposure of > 600mg/m2, the frequency of CHF among PIX 301 recipients was 4% compared to 48% reported for doxorubicin.

               Incidence Clinical CHF- related or unrelated to drug

    Dose (mg/mg2 doxorubicin         Doxorubicin(1)             Pixantrone
    equivalents)                        N=620                      N=70

    <
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma
2. Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session
3. New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis
4. New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohns Patients With Fistulizing Disease
5. Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye
6. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
7. Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School
8. Tanning and Excessive Sun Exposure Can Cause Severe Damage to Eyes
9. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
10. Abbotts HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
11. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... Feb. 27, 2015  Pfenex Inc. (NYSE MKT: PFNX), ... biosimilar therapeutics, today announced that it will be presenting ... on March 2 nd at 3pm PST. Patrick Lucy, ... panel discussing the current state of the biosimilar industry ... For more information on CALBIO 2015 ...
(Date:2/27/2015)... 2015  Steep Hill, the industry leader in cannabis ... to open a full service medical cannabis quality assurance ... bringing advanced scientific tools and methodology to the state, ... is currently the only laboratory licensed by the New ... testing in order to meet the recently adopted regulatory ...
(Date:2/26/2015)... 26, 2015 On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured a ... Genewiz Inc. in excess of $10 million. The jury ... secrets, and that it improperly hired one or more ... motions for judgment notwithstanding the verdict, a new trial, ...
Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... (Nasdaq: ONTY ), a biotechnology company specializing in ... of cancer, today announced that it intends to release ... 11, 2009 after market close. Following the release, Oncothyreon,s ... a general business update in a conference call at ...
... PUNE, India, November 2 TeleDiagnosys based ... services has signed up,several new clients from US and ... Teleradiology services to an international clientele in,countries like USA, ... Teleradiology involves transmitting MRI, CT Scan and ...
... Cardium Therapeutics (NYSE Amex: CXM ) today ... the U.S. Food and Drug Administration (FDA) seeking marketing ... Excellagen XL is an advanced wound care management ... designed for use by physicians in patients with topical ...
Cached Biology Technology:MRI & X-Ray Outsourcing Increasing From Hospitals and Imaging Centers Worldwide 2Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 2Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 3Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 4
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America ... methods for carbon nanotube (CNT) macrostructures, including sheets, yarns ... Dallas (UTD). Leveraging the vast industrial resources ... Tokyo, Japan , Lintec of America is forming ... Richardson, TX , focusing on scaling up the ...
(Date:2/5/2015)... IRVINE, Calif. , Jan. 27, 2015 ... trusted provider of globally deployed, innovative test ... today announced the delivery of its ... Martin Space Systems Company (LMSSC). GENASYS is ... the demands of mission-critical applications that require ...
(Date:2/5/2015)... 2015 Despite a lack of advancements ... as consumer electronics, automotive, storage and telecommunication has ... (SMT) screen printers. Innovations in electronics and conversion ... the adoption curve up. Meanwhile, sale volumes of ... dispensers are indispensable in the production of complex ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3
... Consumption of foods high in carbohydrates immediately after birth ... University at Buffalo animal study has found, even if caloric ... The research on laboratory animals was published this month ... ; it was published online in December. "This is ...
... Braconidae are known for their deadly reproductive habits. Most ... in other insects and their larvae, eventually killing the respective ... sterility. Three new species of the parasitoid wasp genus ... Hymenoptera Research , reflect this fatal behavior. Two ...
... Trademark Office today awarded St. Jude Children,s Research Hospital ... compositions for genetically modifying human immune cells so they ... cancer in children and adults. "This ... attack certain cells that cause leukemia and lymphoma, cancers ...
Cached Biology News:High-carb intake in infancy has lifelong effects, UB study finds 2High-carb intake in infancy has lifelong effects, UB study finds 3Kill Bill character inspires the name of a new parasitoid wasp species 2St. Jude Children's Research Hospital announces issuance of US patent for cancer therapy 2